- Home
- UEIC vs MGNX Comparison
UEIC vs MGNX Comparison
Compare UEIC & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UEIC
- MGNX
- Stock Information
- Founded
- UEIC 1986
- MGNX 2000
- Country
- UEIC United States
- MGNX United States
- Employees
- UEIC N/A
- MGNX N/A
- Industry
- UEIC Consumer Electronics/Appliances
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- UEIC Consumer Staples
- MGNX Health Care
- Exchange
- UEIC Nasdaq
- MGNX Nasdaq
- Market Cap
- UEIC 96.1M
- MGNX 87.7M
- IPO Year
- UEIC 1993
- MGNX 2013
- Fundamental
- Price
- UEIC $6.72
- MGNX $1.33
- Analyst Decision
- UEIC Strong Buy
- MGNX Hold
- Analyst Count
- UEIC 2
- MGNX 9
- Target Price
- UEIC $14.50
- MGNX $5.33
- AVG Volume (30 Days)
- UEIC 30.5K
- MGNX 2.0M
- Earning Date
- UEIC 08-07-2025
- MGNX 08-05-2025
- Dividend Yield
- UEIC N/A
- MGNX N/A
- EPS Growth
- UEIC N/A
- MGNX N/A
- EPS
- UEIC N/A
- MGNX N/A
- Revenue
- UEIC $395,305,000.00
- MGNX $154,050,000.00
- Revenue This Year
- UEIC $3.88
- MGNX N/A
- Revenue Next Year
- UEIC $4.36
- MGNX N/A
- P/E Ratio
- UEIC N/A
- MGNX N/A
- Revenue Growth
- UEIC N/A
- MGNX 255.31
- 52 Week Low
- UEIC $4.32
- MGNX $0.99
- 52 Week High
- UEIC $12.64
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- UEIC 51.34
- MGNX 41.45
- Support Level
- UEIC $6.68
- MGNX $1.33
- Resistance Level
- UEIC $7.50
- MGNX $2.17
- Average True Range (ATR)
- UEIC 0.39
- MGNX 0.17
- MACD
- UEIC -0.07
- MGNX -0.02
- Stochastic Oscillator
- UEIC 43.44
- MGNX 2.38
About UEIC Universal Electronics Inc.
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.